Table 1.
Baseline Characteristics of the Study Population at Initiation of Therapy (n=386)
| Characteristics | Ixekizumab (n=70) | Secukinumab (n=175) | Guselkumab (n=36) | Adalimumab (n=105) | P |
|---|---|---|---|---|---|
| Male, n (%) | 57(81.4) | 119(68) | 28(77.8) | 83(79) | 0.07 |
| Female, n (%) | 13(18.6) | 56(32) | 8(22.2) | 22(21) | |
| Mean age, y (SD) | 42.9(13.4) | 43.1(13.6) | 41.0(9.8) | 44.8(11.9) | 0.43 |
| Mean duration, y (SD) | 14.7(8.3) | 15.9(8.7) | 16.0(10.3) | 15.1(8.9) | 0.77 |
| Mean weight, kg (SD) | 72.7(13.6) | 69.9(13.3) | 75.0(12.6) | 71.8(12.8) | 0.13 |
| Mean BMI, kg/m2 (SD) | 24.9(4.0) | 24.2(3.9) | 25.8(3.9) | 24.6(3.9) | 0.16 |
| Concurrent PsA, n (%) | 6(8.6) | 20(11.4) | 2(5.6) | 28(26.7) | <0.001 |
| Bio-naïve, n (%) | 58(82.9) | 143(81.7) | 20(55.6) | 75(71.4) | 0.002 |
| Previous biological agent | 12 | 32 | 16 | 30 | 0.002 |
| Prior biologic:1 | 8 | 27 | 10 | 26 | |
| Prior biologic:2 | 4 | 3 | 5 | 3 | |
| Prior biologic:3 | 0 | 2 | 1 | 1 | |
| Mean PASI (SD) at baseline | 16.0(6.2) | 16.9(7.0) | 17.6(4.8) | 17.7(5.3) | 0.29 |
| Mean DLQI (SD) at baseline | 12.3(4.8) | 12.7(5.7) | 13.9(4.3) | 14.1(5.5) | 0.07 |
Abbreviations: SD, standard deviation; BMI, body mass index; PsA, psoriatic arthritis; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area Severity Index.